Report Industry Investment Rating No relevant information provided. Core Viewpoints - The Chinese property market shows signs of slight improvement, with the decline in contracted sales in 9M25 narrowing compared to 8M25, and more developers reporting year - on - year increases in September 2025. However, overall sales are still down significantly year - on - year [8][9][10]. - China's social financing flow beat market expectations, but its growth remained weak, and government bond issuance slowed down. Credit demand in the real economy was subdued, and the central bank is likely to maintain ample liquidity and support credit growth with expected cuts in LPR and RRR in 4Q25 [4][12][13]. - China's CPI marginally recovered due to a rebound in food prices, core CPI rose, and PPI narrowed its contraction. Demand - side stimulus and supply - side restructuring are needed to support economic recovery, and a policy easing window is expected in 4Q25 [17][18][19]. Summary by Directory Trading Desk Comments - Yesterday, spreads of some bonds tightened or widened, such as KEBHNB Float 28/KEBHNB 30 tightening 3 - 5bps, KOROIL/HYUELE/HYNMTR belly bonds tightening 1 - 3bps, and PKX widening 1 - 2bps. Japanese AT1s and insurance hybrids firmed, while UBS bonds faced selling [2]. - In Greater China, higher - beta credits like NWDEVLs rose, MTRC perps increased, and some names in Macau gaming also went up. However, LASUDE 26 lost points, and some Chinese property bonds had price changes [2]. - This morning, Asia IG names were 1 - 2bps wider overall, and some bonds like VNKRLE 29/IHFLIN 28/FAEACO 12.814 Perp increased in price, while others decreased [4]. Chinese Properties - In 9M25, the contracted sales of 31 developers dropped 18.5% year - on - year to RMB1,285.6bn. Only 2 state - owned developers reported year - on - year increases, while several others had significant declines [9]. - In September 2025, 31 developers reported contracted sales of RMB136.3bn, a 9.9% year - on - year decrease from RMB151.3bn in September 2024. Nine out of 31 developers reported year - on - year increases in contracted sales, up from 4 in August 2025 [8]. China Economy Credit Weakness with Liquidity Easing - Social financing flows beat market expectations, but outstanding social financing growth edged down to 8.7% in September from 8.8% in August. Government bond issuance contracted, and corporate bond issuance continued to recover [13]. - New RMB loans remained subdued, with growth of outstanding RMB loans edging down to 6.6% in September. Credit demand in the household and corporate sectors was weak [14]. - The central bank is likely to maintain ample liquidity and support credit growth, with expected 10 bps LPR cut and 50 bps RRR cut in 4Q25 [16]. Mild Reflation in Upstream Sectors - China's CPI YoY recovered to - 0.3% in September from - 0.4% in August, and core CPI rose to 1% YoY, the highest since early 2024, indicating a gradual recovery in consumer demand [19][20]. - PPI's year - on - year contraction narrowed to - 2.3% in September from - 2.9%, mainly driven by the rebound in the mining sector, while downstream consumer goods remained subdued [21]. - Policy easing is expected in 4Q25, including a 10bps LPR cut, 50bps RRR cut, and expanding fiscal stimulus towards consumption and the property market [18][23]. Offshore Asia New Issues - Newly priced issues include BOSC International Investment Ltd (USD60mn, 3M, 4.12% coupon), China Water Affairs (USD150mn, 5NC3, 5.875% coupon), and Chengdu Sino French Ecological (USD100mn, 3yr, 4.3% coupon) [25]. - There are no offshore Asia new issues in the pipeline today [26]. News and Market Color - There were 107 credit bonds issued onshore yesterday with an amount of RMB88bn, and month - to - date, 395 credit bonds were issued with a total amount of RMB457bn, a 35.8% year - on - year increase [27]. - Various corporate news, such as BHP considering reviving copper mines, BOCOM redeeming bonds, and CIFIHG unveiling debt restructuring terms [27].

Group 1: Market Overview - The Hang Seng Index closed at 25,911, up 1.84% for the day and 29.17% year-to-date, while the Hang Seng Tech Index rose 2.57% for the day and 35.97% year-to-date [1] - The Chinese stock market rebounded, with sectors like consumer discretionary and staples leading gains, while telecommunications, utilities, and energy lagged [3] - Southbound capital saw a net sell of 5.44 billion HKD, with notable net sells in Hang Seng China Enterprises, Tracker Fund, and SMIC, while Alibaba, Huahong Semiconductor, and Xiaomi received significant net buys [3] Group 2: Economic Insights - The Chinese economy shows signs of weak credit demand, with M1 growth indicating improved business activity, while the central bank is expected to maintain a loose liquidity policy [4][5] - CPI showed a slight recovery, indicating a slow revival in consumer demand, while PPI decline has narrowed due to rising upstream mining prices [4] - The report anticipates a policy easing window in Q4 2025, with expected reductions in LPR and reserve requirement ratios to support consumption and the real estate market [5] Group 3: Company Analysis - Futu Holdings - Futu Holdings is a leading technology-driven financial services platform, covering eight major markets and providing services like securities trading and wealth management [6] - The company is expected to achieve a compound annual growth rate (CAGR) of 12% in revenue and 14% in Non-GAAP net profit from FY25 to FY28, driven by growth in asset clients and improved operational efficiency [5][6] - Futu's AUM in virtual assets reached 4 billion HKD in Q2 2025, with projections indicating it could contribute 2.4 to 3.1 billion HKD in incremental revenue by 2027 [7] Group 4: Investment Rating - The report initiates coverage on Futu Holdings with a "Buy" rating and a target price of 224 USD, supported by its global expansion and strong growth in core business segments [6][7] - The company is currently trading at a significant discount compared to peers, with a P/E ratio of 19x/17x for FY25E/FY26E, presenting an attractive entry point for investors [7]

Market Overview - The global stock markets showed mixed performance, with the Hang Seng Index closing at 25,441, down 1.73% for the day but up 26.83% year-to-date [1] - The US markets experienced slight declines, with the Dow Jones up 0.44% and the S&P 500 down 0.16% [1] - The Chinese stock market saw a third consecutive day of decline, particularly in sectors like materials, healthcare, and information technology, while utilities, telecommunications, and financials outperformed [3] Sector Performance - In the Hong Kong market, the Hang Seng Financial Index remained stable with a slight decrease of 0.01%, while the Hang Seng Industrial Index fell by 2.70% [2] - The public utilities sector showed resilience with a 0.66% increase, contrasting with the declines in real estate and industrial sectors [2] Company Insights - J&T Express reported a 23% year-on-year increase in parcel volume for Q3 2025, driven by a significant 79% growth in Southeast Asia, while growth in China slowed to 10% [5] - Baidu is expected to report Q3 2025 core business revenue of 24.6 billion RMB, a 7% decline year-on-year, primarily due to the ongoing transformation of its advertising business [5] - Baidu's cloud business is anticipated to grow by 20% year-on-year, partially offsetting the decline in advertising revenue [5] Economic Indicators - China's tax revenue data indicates an improvement in corporate revenue growth, with year-on-year growth rates of 2.6% and 6.9% for the second and third quarters, respectively [3] - The IEA's monthly report suggests a potential record oil surplus next year, estimated at nearly 4 million barrels per day [4] Investment Sentiment - Investor sentiment in the US stock market has shifted to an overweight position, reaching an eight-month high, with cash holdings dropping to a low of 3.8% [3] - Concerns about potential bubbles in AI stocks and high global stock valuations were noted, with 54% of surveyed investors expressing such concerns [3]

Report Industry Investment Rating - Not provided in the given content Core Viewpoints - Due to the escalation of US-China tensions, the Asia IG space widened 3-7bps across the board yesterday, with better selling on certain bonds and better buying on others [2] - China's export resilience strengthens its position in the trade war, leading to a revision of the 2025 export growth forecast from 3% to 4.5%, while maintaining the 2025 import growth forecast at 1.5%. The USD/RMB rate may appreciate from 7.13 to 7.1 by year-end and 7.05 by the end of 2026 [4][15][20] - China Water Affairs (CWAHK) proposes to issue a 5NC3 USD senior blue bond, with the FV of the new CWAHK 30 estimated at 6% [8] Summary by Directory Trading Desk Comments - Asia IG space widened 3-7bps due to US-China tension, with better selling on TW lifers, China TMTs, Japanese banks' bonds, and Southeast Asian names. Some bonds like FAEACO 12.814 Perp and NWDEVLs/LIFUNGs/FOSUNI 26 - 29s decreased in price. In Chinese properties, VNKRLE 27 - 29s and FTLNHD 26/FUTLAN 28 were lower, while some SOE property names had better buying. In Southeast Asia, VLLPM 27 - 29s edged up, and VEDLN 28 - 33s/GLPSPs were down. Long - end Yankee AT1s weakened in the morning and recovered slightly [2] - In the LGFV space, activities picked up with new CNH issues, and the space had a stable session with moderate two - way flows [3] - This morning, there were two - way flows on LGFV names. HAOHUAs recovered 3 - 5bps and HYUELEs recovered 5bps in Asia IG space, while NOMURA and Australian long - end Ts2 widened 2 - 3bps. CWAHK 26 had buyers and was 0.1pt higher [4] Marco News Recap - On Monday, S&P (+1.56%), Dow (+1.29%), and Nasdaq (+2.21%) were higher. The US bond market was closed for Columbus Day, and the UST yield was unchanged, with 2/5/10/30 yield at 3.52%/3.65%/4.05%/4.63% [7] Desk Analyst Comments - CWAHK proposes to issue a 5NC3 USD senior blue bond (Ba1/BB+/-), with the FV of the new CWAHK 30 at 6% considering its CWAHK 26 and peers' valuations, adjusted for rating and tenor differential. The issuance size should be capped at its remaining offshore - issuance quota of USD200mn [8] - The net proceeds will be used to repay offshore debt and finance eligible green projects. The new CWAHK 30 will have a CoC put at 101 [10] - CWAHK is a holding company operating mainly through PRC subsidiaries. The new CWAHK 30 will be guaranteed by non - PRC - incorporated subsidiary guarantors [11] - CWAHK is one of the largest water supply companies in China, focusing on water supply and sewage treatment, generating stable cash flow from exclusive concession rights in 58 districts. It serves various end - users with potential coverage of over 30mn people [12] - In FY25, CWAHK generated HKD11.7bn of revenue and HKD3.4bn of operating cash flow, with an estimated free cash flow of HKD40mn. Total debt was HKD25.6bn, and its operating performance weakened, with revenue and EBIT down c9%. Coverage ratios also weakened [13] - CWAHK is listed in Hong Kong, with the chairman and founder owning 27.4%, ORIX Corp and affiliates holding 27.2%, and Great Wall Life Insurance holding 6.0% [14] China Economy - China's export growth beat expectations as exports to Africa, Latin America, and the EU picked up. Exports of integrated circuits and ships remained robust, while personal consumption goods were subdued. Imports rebounded across the board, especially in processing trade. China's rare earth export control is a countermeasure to US semiconductor export restrictions. Trade tensions may intensify in the next two weeks before potentially easing after a possible Trump - Xi meeting [15] - Exports rebounded in September, reaching 8.3% YoY from 4.4% in August, beating market expectations. Exports to the US remained in deep contraction, while shipments to Africa, the EU, and Latin America accelerated. Exports to ASEAN moderated. Since the tariff shocks, exports to ASEAN and Africa have increased significantly, making up for over 120% of the export losses to the US since April. Trade surplus narrowed to US$91bn in September [16] - Integrated circuits and ships had strong growth in September, while personal consumption goods moderated. Low - value - added exports and housing - related products were hit by tariffs. Rare earth exports rebounded despite additional export controls [17] - China's imports increased to 7.4% in September from 1.3% in August, beating market expectations. Imports from the US steadied at - 16%. Import value of processing trade accelerated. For energy products, crude oil import volume rose, while coal and natural gas dropped. Raw material imports had mixed results, and crop imports picked up [18] Offshore Asia New Issues - No offshore Asia new issues were priced today [22] - There are several issuers in the pipeline, including the Macau Branch of Bank of China Limited, Jinan Hi - tech International, and KEB Hana Bank, with different tenors, coupons, and issue ratings [23] News and Market Color - Yesterday, 118 credit bonds were issued onshore with an amount of RMB138bn. Month - to - date, 191 credit bonds were issued with a total amount of RMB212bn, a 19.7% yoy increase [24] - Indonesia plans to shorten the permit process for geothermal projects to three months [24] - Country Garden's top shareholder agrees to a USD1.14bn debt - to - equity swap and will hold scheme meetings on 5 Nov'25 for creditors to vote on its offshore restructuring plan [24] - Freeport Indonesia halts the Gresik smelter due to a mine landslide [24] - China Energy Overseas will redeem GEZHOU 4.15 Perp of USD200mn on 25 Nov'25 [24] - LG Electronics expects a 8.4% yoy drop in 3Q25 operating profit due to higher tariffs [24]

Group 1: Market Overview - Global stock markets showed mixed performance, with the Hang Seng Index declining by 1.52% while the US markets rebounded, with the Dow Jones increasing by 1.29% [1][3] - The Southbound capital saw a net buy of HKD 19.804 billion, with notable inflows into the Tracker Fund, Hang Seng China Enterprises, and Hua Hong Semiconductor, while Tencent, Alibaba, and SMIC faced net selling [3] Group 2: Chinese Market Insights - The Chinese stock market experienced a continuous pullback, particularly in healthcare, information technology, and consumer discretionary sectors, while materials and utilities sectors saw gains [3] - China's exports showed resilience, with a year-on-year growth of 8.3% in September, driven by strong demand for industrial robots and wind power equipment, while imports also rebounded significantly [4] Group 3: Company Analysis - JD.com - JD.com is expected to report total revenue of RMB 295 billion for Q3 2025, reflecting a year-on-year growth of 13.3%, aligning with Bloomberg's consensus [4] - The non-GAAP net profit for JD.com is projected at RMB 4.4 billion, a decline of 67% year-on-year due to increased investments in the delivery business, but better than the market consensus of RMB 3.7 billion [4] - The operating profit for JD's retail segment is anticipated to grow by 17% year-on-year, exceeding market expectations due to improved scale effects and a higher proportion of high-margin service revenue [4]

Market Strategy Overview - The report indicates that the second phase of the bull market is underway, driven by strong domestic demand and policy support in the AI and semiconductor sectors [2][3]. Domestic Market Insights - The domestic computing power chain is experiencing a comprehensive cyclical resonance, with significant policy and market demand acceleration, exemplified by the successful listing of Moer Thread on September 26 [3]. - AI-driven storage sector prices are expected to see double-digit growth, with TrendForce predicting substantial increases in DDR4/DDR5 contract and spot prices, leading to a price-volume resonance in wafer manufacturing and semiconductor production equipment [3]. Future Outlook - Over the next three months, global computing power investment is expected to maintain high levels of prosperity, with capital expenditures in AI infrastructure still in the expansion phase [4]. - Companies such as Broadcom and AMD are rapidly emerging outside of Nvidia's dominance, while domestic computing power chains are entering a realization phase with high certainty in growth across GPU, storage, wafer manufacturing, and equipment sectors [4]. - AI inference demand is extending to end-user applications, with smart driving and AI terminal applications becoming key growth drivers [4]. Recommended Stocks - The report recommends several stocks for investment, including: - Zhongji Xuchuang (300308 CH, Buy) - Shengyi Technology (600183 CH, Buy) - Horizon Robotics (9660 HK, Buy) - Shenzhen South Circuit (002916 CH, Buy) - Beike Micro (2149 HK, Buy) - Northern Huachuang (002371 CH, Buy) [4]. Macro Economic Context - The report notes a slowdown in the Chinese economy, with GDP growth expected to decline from 5.2% in Q2 to 4.9% in Q3 and 4.6% in Q4, with an annual forecast of 5% [11]. - The report highlights that the macroeconomic environment is likely to see a renewed push for fiscal policy in Q4, with potential interest rate cuts and increased government spending to stimulate consumption [14]. Sector-Specific Insights - In the technology sector, optimism is noted for Q3, with strong sales expected for the iPhone 17 and continued growth in AI server deployments [5]. - The semiconductor sector is also viewed positively, with significant investments in AI infrastructure and partnerships between major players like OpenAI and Broadcom [5]. - The report emphasizes the importance of AI in driving growth across various sectors, including healthcare, industrials, and consumer staples, with specific recommendations for stocks in these areas [5][6]. Consumer Behavior Trends - The report identifies a cautious but improving consumer sentiment, with expectations for increased spending in essential consumer goods and sectors benefiting from domestic brand replacements [7]. - The report suggests that consumer behavior is gradually adapting to economic pressures, leading to potential growth in sectors like snacks, soft drinks, and beer [7].

Market Overview - Global markets experienced a decline, with the Hang Seng Index dropping by 1.73% and the Nasdaq falling by 3.56% [1][3] - The Chinese stock market faced significant pullbacks due to escalating trade tensions with the U.S., leading to increased risk aversion among investors [3] Industry Insights - The Chinese pharmaceutical sector has seen a 74.9% increase in the MSCI China Healthcare Index since early 2025, outperforming the MSCI China Index by 35.8% [4] - Recent pullbacks in the healthcare sector present buying opportunities, driven by a recovery in capital market financing and an increase in demand for innovative drug development [4][6] - The market is advised to focus on the clinical progress of authorized innovative drug pipelines overseas, which could enhance their value [4] Company Analysis - China Biologic Products (1177 HK) has shown promising results with its PDE3/4 inhibitor TQC3721 in Phase II clinical trials, indicating significant potential for improving lung function in COPD patients [6][7] - TQC3721 demonstrated a peak FEV1 improvement of 147ml compared to the placebo group, suggesting its potential as a leading treatment option in the COPD market [8][9] - The global COPD market is substantial, with nearly 480 million affected individuals, highlighting the significant market potential for TQC3721 [9] - China Biologic Products maintains a "Buy" rating with a target price of HKD 9.40, anticipating revenue growth rates of +19.1% for 2025 [10]

Investment Rating - The report maintains a "Buy" rating for the company, with a target price of HKD 9.40, indicating a potential upside of 20.5% from the current price of HKD 7.80 [4][10]. Core Insights - The clinical data for the PDE3/4 inhibitor TQC3721 shows promising results, with significant improvements in lung function and symptoms for patients with severe COPD after 4 weeks of treatment [1][2]. - TQC3721 is positioned as the second globally in development and the only PDE3/4 inhibitor currently in Phase III clinical trials, suggesting substantial market potential and opportunities for licensing [10][12]. - The financial projections indicate a revenue growth of 19.1% for FY25E, with adjusted net profit expected to increase by 81.3% in the same year [3][13]. Financial Summary - Sales revenue (in million RMB) is projected to grow from 26,199 in FY23A to 34,380 in FY25E, reflecting a year-on-year growth of 19.1% [3][17]. - Adjusted net profit is expected to rise from 2,589 in FY24A to 6,267 in FY25E, marking an increase of 81.3% [3][13]. - The adjusted earnings per share (EPS) is forecasted to reach RMB 0.33 in FY25E, with a corresponding adjusted P/E ratio of 21.6 [3][10]. Clinical Data Highlights - In the Phase II clinical trial, TQC3721 demonstrated a peak FEV1 improvement of 147ml compared to the placebo group, aligning with the results of the approved competitor, ensifentrine [2][10]. - The safety profile of TQC3721 is favorable, with no significant adverse effects reported in gastrointestinal, cardiovascular, or renal functions during the trials [1][10]. Market Context - The global COPD market is substantial, with nearly 480 million affected individuals, and TQC3721's development is timely given the increasing demand for effective treatments [10][12]. - The competitive landscape is highlighted by the recent FDA approval of ensifentrine, which underscores the potential for TQC3721 to capture market share as it progresses through clinical trials [10][12].

Investment Rating - The report assigns a "Buy" rating to several companies in the Chinese pharmaceutical sector, indicating a potential upside of over 15% in the next 12 months [31]. Core Insights - The MSCI China Healthcare Index has increased by 74.9% since early 2025, outperforming the MSCI China Index by 35.8%. A recent 3% decline in the healthcare sector presents a buying opportunity due to a recovery in capital market financing and an increase in overseas transactions for innovative drugs [1][4]. - The report emphasizes the importance of clinical advancements for authorized innovative drug pipelines overseas, which are expected to act as catalysts for stock price increases [4]. - The outlook for the innovative drug sector remains positive, driven by overseas partnerships and clinical progress, while consumer healthcare is also seen as having valuation recovery potential [4]. Summary by Sections Industry Investment Rating - The report indicates that the healthcare sector is expected to outperform the market in the next 12 months [32]. Company Ratings and Valuations - **Sangfor Pharma (1530 HK)**: Buy, Market Cap: $8,785 million, Target Price: $37.58, Upside: 34%, FY25E P/E: 6.8 [2]. - **Giant Biologics (2367 HK)**: Buy, Market Cap: $7,357 million, Target Price: $71.30, Upside: 33%, FY25E P/E: 22.5 [2]. - **WuXi AppTec (2268 HK)**: Buy, Market Cap: $11,068 million, Target Price: $74.00, Upside: 3%, FY25E P/E: 52.2 [2]. - **Gushengtang (2273 HK)**: Buy, Market Cap: $984 million, Target Price: $48.28, Upside: 54%, FY25E P/E: 16.1 [2]. - **China National Pharmaceutical Group (1177 HK)**: Buy, Market Cap: $18,809 million, Target Price: $9.40, Upside: 21%, FY25E P/E: 21.1 [2]. - **Innovent Biologics (1801 HK)**: Buy, Market Cap: $20,683 million, Target Price: $109.48, Upside: 17%, FY25E P/E: 147.8 [2]. Market Trends and Future Outlook - The report highlights a recovery in the demand for innovative drug research and development in China, supported by a resurgence in capital market financing and a favorable environment for overseas clinical trials [1][4]. - The report also notes that the U.S. remains a significant market for Chinese innovative drugs, despite recent pricing agreements that may affect short-term revenues [4].

Macro Overview - The report indicates a cautious optimism regarding China's holiday economy, with moderate growth in consumption during the National Day holiday. Key trends include strong performance in green, smart, and experiential consumption [2][4] - Despite recent relaxations in real estate policies in first-tier cities, the real estate market remains weak, with a significant year-on-year decline in new and second-hand housing sales [3][6] - The report anticipates that core CPI and PPI growth will rebound, alleviating deflationary pressures, with liquidity conditions expected to remain loose for at least the next two quarters [2][7][8] Internet Sector - The online travel agency (OTA) sector shows resilience, with keywords "quality" and "long-distance travel" indicating strong demand. Long-distance travel bookings on Ctrip increased by 3 percentage points year-on-year [28][30] - During the holiday, Alibaba's Fliggy reported a 14.6% year-on-year increase in average transaction value, while Tongcheng Travel noted nearly 100% growth in outbound group travel bookings [28][31] - The report maintains a "buy" rating for Ctrip (TCOM US) and Tongcheng Travel (780 HK) based on these positive trends [28] Consumer Discretionary - The report expresses a cautious outlook for retail sales growth during the 2025 National Day holiday, attributing potential risks to high base effects from 2024, lack of government subsidies, and ongoing macroeconomic pressures [32][35] - The report highlights a preference for consumer downgrade themes and high-dividend stocks, with concerns over profit margin pressures due to increased competition and discounting [32][35] Automotive Sector - The report notes a significant divergence in sales during the National Day holiday, with new energy vehicles (NEVs) outperforming traditional fuel vehicles. The introduction of popular NEV models is expected to drive order growth [6][32] - The forecast for national passenger vehicle retail and wholesale sales in 2025 has been slightly raised, reflecting better-than-expected sales in Q3 and potential pre-purchase demand for NEVs [6][32] Real Estate Sector - The report indicates that the effectiveness of real estate policies is diminishing, with a notable decline in sales volume for new and second-hand homes during the holiday period [3][6] - The report anticipates that further easing measures may be necessary to stimulate housing demand, as sales data remains weak despite policy support [3][6] Selected Stocks - The report identifies several preferred stocks, including Luckin Coffee (LKNCY US), Guoquan (2517 HK), Green Tea Group (6831 HK), Jiumaojiu (9922 HK), Li Ning (2331 HK), Bosideng (3998 HK), and JS Global Life (1691 HK) [33][41]